Welcome to our dedicated page for Imunon news (Ticker: IMNN), a resource for investors and traders seeking the latest updates and insights on Imunon stock.
Imunon, Inc. (IMNN) generates frequent news as a clinical-stage biotechnology company advancing DNA-mediated immunotherapies and DNA vaccine technologies. Most coverage centers on its lead program, IMNN-001, a TheraPlas-based IL-12 DNA immunotherapy in Phase 3 development for newly diagnosed advanced ovarian cancer, and on its PlaCCine DNA vaccine platform, including the IMNN-101 COVID-19 booster candidate.
Investors following IMNN news can expect regular updates on clinical trial progress, such as enrollment milestones, translational data and survival outcomes from the OVATION 2 Phase 2 study and the pivotal OVATION 3 Phase 3 trial. Company releases describe how IMNN-001 is being evaluated in combination with standard neoadjuvant and adjuvant chemotherapy, and how biomarker data show shifts in the tumor microenvironment toward more active anti-tumor immunity.
Another major news theme is scientific and medical conference activity. Imunon frequently announces posters and presentations at meetings such as the Society for Immunotherapy of Cancer, the European Society for Medical Oncology, the International Gynecologic Cancer Society and specialized ovarian cancer conferences. These items often include new translational data on immune cell changes, cytokine profiles and clinical outcomes associated with IMNN-001.
Imunon also issues news on corporate and financial developments, including quarterly financial results, R&D Day events, capital markets transactions like registered direct offerings and at-the-market equity programs, and Nasdaq listing-related updates. For the PlaCCine platform, news items highlight proof-of-concept data for IMNN-101 and presentations at international vaccine conferences.
For readers tracking IMNN, this news feed provides a consolidated view of clinical milestones, scientific recognition, financing activities and regulatory communications that shape the company’s development trajectory in oncology and DNA vaccine research.
IMUNON (Nasdaq: IMNN) will host an R&D Day on Monday, November 10, 2025 at 8:00 a.m. ET in New York City with a live webcast option. The event features principal investigators discussing clinical progress for IMNN-001, a DNA-mediated IL-12 immunotherapy in Phase 3 development for advanced ovarian cancer, plus Phase 2 MRD results and Phase 3 statistical design.
Speakers include investigators from Washington University, MD Anderson, Berry Consultants, and IMUNON leadership covering OVATION 3/OVATION 2 data, MRD trial immune activation, trial design, enrollment momentum, and near-term clinical milestones. Registration is required to attend in person or virtually.
IMUNON (Nasdaq: IMNN) will host a Third Quarter 2025 Financial Results and Business Update conference call on Thursday, November 13, 2025 at 11:00 a.m. ET. The company will discuss results for the quarter ended September 30, 2025 and provide an update on its Phase 3 clinical development program for IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy.
Dial-in numbers are provided for North America and international participants, a live webcast will be available, and the call will be archived for replay through November 27, 2025 with an audio replay accessible for 90 days.
IMUNON (NASDAQ: IMNN) will host an in-person and virtual R&D Day in New York City on November 10, 2025 at the Harvard Club, starting at 8:00 a.m. ET.
The program will provide updates on the pivotal Phase 3 OVATION 3 study and Phase 2 MRD trial for IMNN-001, featuring presentations from ovarian cancer clinicians, Phase 3 investigators, statistical experts, and IMUNON management on safety, translational data, trial design and IMNN-001’s potential role in advanced ovarian cancer. The event includes a live Q&A and networking with speakers.
Registration is available for in-person or virtual attendance via RSVP.
IMUNON (Nasdaq: IMNN) will present a trials-in-progress poster on its pivotal Phase 3 OVATION 3 trial of IMNN-001 at the International Gynecologic Cancer Society Annual Global Meeting, Nov 5-7, 2025 in Cape Town.
IMNN-001 is a DNA-mediated IL-12 plasmid delivered by nanoparticle (TheraPlas platform). The company treated the first patient in July 2025, has activated 4 sites, and is considering up to 46 additional sites to accelerate enrollment. The same TiP poster was also accepted at ESMO 2025.
Poster: "OVATION-3: A randomized phase III trial..." Presenting author: Douglas V. Faller, M.D., Ph.D. Poster number: TP014/#750.
IMUNON (Nasdaq: IMNN) will present new translational data from the Phase 2 OVATION 2 study of IMNN-001 at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting on November 7, 2025 (Poster #1165, 12:15–1:45 PM ET).
IMNN-001 is a DNA-encoded IL-12 therapy using the TheraPlas® nanoparticle delivery platform. The company says OVATION 2 showed a clinically effective response in newly diagnosed advanced (stage IIIC/IV) epithelial ovarian cancer, including reported benefits in progression-free survival and overall survival, increases in key anti-cancer cytokines, and modulation of immune cell populations (CD8+ T cells, myeloid dendritic cells). IMNN-001 is advancing into the pivotal OVATION 3 Phase 3 trial per plan.
IMUNON (Nasdaq: IMNN) will host an R&D Day for investors on November 10, 2025 at the Harvard Club in New York City, starting at 8:00 a.m. ET.
The program will provide updates on the pivotal Phase 3 OVATION 3 study of IMNN-001 and a Phase 2 MRD trial, featuring presentations from ovarian cancer clinical leaders, Phase 3 investigators, statistical experts and IMUNON management. Presentations will cover safety, translational insights, trial design probability of success, and an OVATION 3 trial update, followed by a live Q&A and networking.
IMUNON (Nasdaq: IMNN) announced oral presentations of PlaCCine® DNA vaccine proof-of-concept data and IMNN-101 clinical results at two vaccine conferences: Oct 23, 2025 (International Vaccines Congress, Orlando) and Nov 6, 2025 (International Conference on Vaccine Research and Development, Boston).
IMNN reported positive six-month Phase 1 data showing better durability versus mRNA after a single dose targeting SARS-CoV-2 Omicron XBB1.5, with up to a 3-fold median increase in serum neutralizing antibody titers at six months and stronger responses in the 2.0 mg and 1.0 mg cohorts. IMNN-101 was safe and well tolerated with no serious adverse effects. The company is seeking strategic partners to advance PlaCCine commercialization, highlighting durability, temperature stability, and scalable manufacturing.
IMUNON (Nasdaq: IMNN) will present a trials-in-progress poster on its pivotal Phase 3 OVATION 3 study of IMNN-001 at the European Society for Medical Oncology (ESMO) Congress, October 17–21, 2025 in Berlin.
IMNN-001 is an IL-12 DNA plasmid delivered in a nanoparticle to elicit local tumor immune responses. The company announced the first patient treated in July 2025, has activated 4 sites, and is considering up to 46 additional sites to accelerate enrollment. The poster (No. 1234eTiP) will be presented by Dr. Premal H. Thaker and posted on IMUNON’s Scientific Presentations page after the conference.
IMUNON (NASDAQ: IMNN) presented promising new translational data from its Phase 2 OVATION 2 Study of IMNN-001, a DNA-mediated immunotherapy for advanced ovarian cancer. The study, involving 112 participants, demonstrated significant improvements in the tumor micro-environment (TME) through the local administration of IL-12 immunotherapy.
Key findings showed a positive TME shift in the majority of participants, with 50-80% of samples showing increased anti-tumor cells and 65-80% showing decreased immunosuppressive markers. The therapy effectively transformed "cold" tumors to "hot" by activating both innate and adaptive immune systems, while maintaining a favorable safety profile.
The company has initiated its pivotal Phase 3 OVATION 3 Study with four active trial sites currently enrolling patients.
IMUNON (NASDAQ: IMNN) announced it will present new translational data from its Phase 2 OVATION 2 Study of IMNN-001 at the AACR Special Conference in Cancer Research. IMNN-001 is a DNA-mediated immunotherapy for newly diagnosed advanced ovarian cancer currently in Phase 3 development.
The therapy utilizes IMUNON's TheraPlas® technology platform, incorporating an IL-12 DNA plasmid vector into a nanoparticle delivery system. It has demonstrated clinical effectiveness in advanced ovarian cancer, showing benefits in both progression-free survival and overall survival when combined with standard chemotherapy.
The presentation, titled "IMNN-001, an IL-12 gene therapy, added to Neo/Adjuvant chemotherapy safely turns the tumor microenvironment cold-to-hot in newly diagnosed epithelial ovarian cancer (EOC)," will be delivered by Dr. Douglas V. Faller, Chief Medical Officer, on September 20, 2025.